


Claims

1. A compound of formula (I)



5 wherein

— is a single bond or a double bond;

X^1 is $(CR^{x^1}H)_n$ and X^2 is $(CH)_n$; or

X^1 is $(CR^{x^1}H)_n$ and X^2 is N ; or

X^1 is NR^{x1} and X^2 is (CH); or

10 X^1 is $\mathbb{N}R^{x^1}$ and X^2 is $\mathbb{N}$; or

X¹ is N and X² is C; wherein the bond between X¹ and X² is a double bond if X¹ is N and X² is C;

n is 0 or 1;

R^{x1} is selected from hydrogen and C₁₋₆alkyl;

15 m is 1 and p is 0; or

m is 1 and p is 1; or

m is 2 and p is 1;

Y is NR¹ or O;

20 R¹ is selected from hydrogen, C₁₋₆alkyl, -C₁₋₄alkylC(O)NR^{1a}R^{1b}, -C₁₋₄alkylC(O)OC₁₋₄alkyl, -C₁₋₄alkylC(O)OC₁₋₄haloalkyl, C₁₋₆haloalkyl, C₃₋₆cycloalkyl, -C₁₋₄alkyl-5-6 membered heteroaryl, hydroxyC₁₋₆alkyl, C₁₋₆alkoxy and C₁₋₄alkoxyC₁₋₄alkyl;

wherein the 5-6 membered heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from halogen and C₁₋₆alkyl;

R^{1a} and R^{1b} are independently selected from hydrogen, C₁₋₆alkyl and C₁₋₆haloalkyl; or R^{1a}

25 and R^{1b} together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring containing 0, 1 or 2 additional heteroatoms selected from oxygen, nitrogen and sulphur;

R^{2a} is selected from

(i) -A-phenyl;

30 (ii) -A-5-6 membered heteroaryl;

(iii) -A-4-6 membered heterocyclyl;

(iv) -A-C₅₋₆cycloalkyl;

(v) -D-8-10 membered fused bicyclic ring system;

wherein the phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, C₅₋₆cycloalkyl and 8-10 membered fused bicyclic ring system are unsubstituted or substituted with 1 to 3 substituents independently selected from halogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy and C₁₋₆haloalkyl;

A is selected from a bond, -(CR^{A1}R^{A2})-, -(CR^{A1}R^{A2})(CR^{A1}R^{A2})-, -(CR^{A1}R^{A2})-O-, -O-(CR^{A1}R^{A2})-, -(CR^{A1}R^{A2})-S-, -(CR^{A1}R^{A2})-S(O)-, -(CR^{A1}R^{A2})-S(O)₂-, -S-(CR^{A1}R^{A2})-, -S(O)-(CR^{A1}R^{A2})-, -S(O)₂-(CR^{A1}R^{A2})-, -NR^{A3}-(CR^{A1}R^{A2})-, -(CR^{A1}R^{A2})-NR^{A3}- and -(CR^{A1})=(CR^{A1})-;

D is a bond, -O- or -(CR^{D1}R^{D2})-;

R^{A1}, R^{A2} and R^{A3} are independently selected from hydrogen, C₁₋₆alkyl and halogen;

R^{D1} and R^{D2} are independently selected from hydrogen, C₁₋₆alkyl and halogen;


R^{2b} is hydrogen or C₁₋₄alkyl;

R³ and R⁴ are independently selected from hydrogen, C₁₋₆alkyl and C₃₋₆cycloalkyl; or R³ and R⁴ together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring containing 0, 1 or 2 additional heteroatoms selected from oxygen, nitrogen and sulphur; which 4-6 membered heterocyclic ring is unsubstituted or substituted with 1 or 2 halogen substituents;

R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆hydroxyalkyl and C₁₋₆haloalkyl;

R⁵ is selected from phenyl, a 5-6 membered heteroaryl, C₃₋₆cycloalkyl and 4-6 membered heterocyclyl; which phenyl, 5-6 membered heteroaryl, C₃₋₆cycloalkyl and 4-6 membered heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from halogen, C₁₋₆alkyl, C₁₋₆alkoxy and C₁₋₆haloalkyl; or a pharmaceutically acceptable salt thereof.


2. The compound according to claim 1, wherein the compound is of formula (Ia)



wherein X¹ is (CR^{x1}H)_n and X² is (CH) or X¹ is NR^{x1} and X² is (CH).

3. The compound according to claim 1, wherein the compound is of formula (Ib)


175



(lb),


wherein X^1 is $(CR^{x1}H)_n$ and X^2 is (CH) or X^1 is NR^{x1} and X^2 is (CH) .

4. The compound according to claim 1, wherein the compound is of formula (lc)




(lc).

5. The compound according to claim 1, wherein the compound is of formula (ld)



(ld).


6. The compound according to claim 1, wherein the compound is of formula (le)



(le),

wherein X^1 is $(CR^{x1}H)_n$ and X^2 is (CH) or X^1 is NR^{x1} and X^2 is (CH) .


7. The compound according to claim 1, wherein the compound is of formula (lf)



(lf),


wherein X^1 is $(CR^{x1}H)_n$ and X^2 is (CH) or X^1 is NR^{x1} and X^2 is (CH) .

8. The compound according to claim 1, wherein the compound is of formula (lg)



wherein X^1 is $(CR^{x1}H)_n$ and X^2 is (CH) or X^1 is NR^{x1} and X^2 is (CH) .

9. The compound according to claim 1, wherein the compound is of formula (lh)



wherein X^1 is $(CR^{x1}H)_n$ and X^2 is (CH) or X^1 is NR^{x1} and X^2 is (CH) .

10. The compound according to any one of claims 1 to 9, wherein Y is NR^1 .

11. The compound according to any one of claims 1 to 10, wherein Y is NR^1 and R^1 is selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, $-C_{1-4}alkylC(O)NR^{1a}R^{1b}$, $-C_{1-4}alkylC(O)OC_{1-4}alkyl$, and $-C_{1-4}alkyl-5-6$ membered heteroaryl, wherein the 5-6 membered heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from halogen and C_{1-6} alkyl.

12. The compound according to any one of claims 1 to 11, wherein X^1 is $(CR^{x1}H)_n$.

13. The compound according to any one of claims 1 to 4, wherein X^1 is $(CR^{x1}H)_n$ and n is 1.

14. The compound according to any one of claims 1 to 13, wherein R^5 is selected from phenyl and a 5-6 membered heteroaryl, which phenyl or 5-6 membered heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from halogen and C_{1-6} alkyl.

15. The compound according to any one of claims 1 to 14, wherein R^{2a} is selected from -A-phenyl, -A-5-6 membered heteroaryl, -A-4-6 membered heterocyclyl, -A- C_{5-6} cycloalkyl and a -D-8-10 membered fused bicyclic ring system, which phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, -A- C_{5-6} cycloalkyl and 8-10 membered fused bicyclic ring

system are unsubstituted or substituted with 1 to 3 substituents independently selected from C₁₋₆alkyl, C₁₋₆alkoxy and halogen.

16. The compound according to any one of claims 1 to 15, wherein R³ and R⁴ are both
5 hydrogen.

17. The compound according to any one of claims 1 to 16, wherein R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl and C₁₋₆hydroxyalkyl.

- 10 18. A compound according to claim 1, which is selected from
2-Amino-N-[(R)-1-benzyloxymethyl-2-(2-methyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl]-2-methyl-propionamide;
2-Amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro
[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
15 2-Amino-N-((2R)-3-(benzyloxy)-1-oxo-1-(1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)propan-2-yl)-2-methylpropanamide;
2-Amino-N-((2R)-3-(benzyloxy)-1-(2-isopropyl-1-oxo-4-phenyl-2,7-diaza spiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
2-Amino-N-((2R)-3-(benzyloxy)-1-(4-(4-chlorophenyl)-2-methyl-1-oxo-2,7-diaza
20 spiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
2-Amino-N-((2R)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
2-Amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-3-(1-methyl-1H-indol-3-yl)-1-oxopropan-2-yl)propanamide;
25 2-amino-N-((2R)-3-(benzyloxy)-1-(2-ethyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
2-Amino-N-((2R)-1-(4-(4-fluorophenyl)-2-isopropyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(1-methyl-1H-indol-3-yl)-1-oxopropan-2-yl)-2-methyl propanamide;
2-amino-N-((2R)-3-(benzyloxy)-1-(2-(2-(dimethylamino)-2-oxoethyl)-1-oxo-4-phenyl-2,7-
30 diaza spiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
N-((2R)-3-(Benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methyl-2-(methylamino) propanamide;
2-Amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-isopropyl-1-oxo-2,7-
diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
35 2-Amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro [4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

- N-((2R)-3-(1H-indol-3-yl)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-amino-2-methylpropanamide;
2-amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-5-phenylpentan-2-yl)propanamide;
- 5 2-amino-N-((2R)-3-(benzyloxy)-1-(2-ethyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
2-amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-4-phenylbutan-2-yl)propanamide;
2-amino-N-((2R)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(4-methylbenzyloxy)-1-oxopropan-2-yl)-2-methylpropanamide;
- 10 2-amino-N-((2R)-3-(3-methoxybenzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
2-amino-N-((2R)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-5-phenylpentan-2-yl)-2-methylpropanamide;
- 15 2-amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-5-phenylpentan-2-yl)propanamide;
2-amino-N-((2R)-1-(4-(4-fluorophenyl)-2-isopropyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
2-amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-3-phenyl-2,6-diazaspiro[3.5]nonan-6-yl)-3-(1-methyl-1H-indol-3-yl)-1-oxopropan-2-yl)propanamide;
- 20 2-Amino-N-((R)-1-benzyloxymethyl-2-[2-(2,2-dimethyl-propyl)-1-oxo-4-phenyl-2,7-diazaspiro[4.5]dec-7-yl]-2-oxo-ethyl)-2-methyl-propionamide;
2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxobutan-2-yl)-2-methylpropanamide;
- 25 2-amino-N-((2R)-3-(benzyloxy)-1-(1-(4-fluorophenyl)-2-methyl-3-oxo-2,6-diazaspiro[3.5]nonan-6-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
2-Amino-N-((R)-1-benzyloxymethyl-2-(2-isobutyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl)-2-methyl-propionamide;
2-Amino-N-((R)-1-benzyloxymethyl-2-[4-(4-chloro-phenyl)-2-methyl-1-oxo-2,7-diaza-spiro[4.5]dec-7-yl]-2-oxo-ethyl)-2-methyl-propionamide;
- 30 2-Amino-N-((R)-1-benzyloxymethyl-2-(2-isopropyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl)-2-methyl-propionamide;
2-Amino-N-((R)-1-benzyloxymethyl-2-(3-methyl-4-oxo-1-phenyl-2,3,7-triaza-spiro[4.5]dec-1-en-7-yl)-2-oxo-ethyl)-2-methyl-propionamide;
- 35 2-Amino-N-((R)-1-benzyloxymethyl-2-(3-methyl-4-oxo-1-phenyl-1,3,7-triaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl)-2-methyl-propionamide;

- 2-Amino-N-[(R)-1-benzyloxymethyl-2-oxo-2-(1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-ethyl]-2-methyl propionamide;
- 2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-o-tolyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 5 2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-p-tolyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 2-amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-3-(4-methylbenzyloxy)-1-oxopropan-2-yl)propanamide;
- 2-amino-N-((2R)-3-(4-chlorobenzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 10 2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-(pyridin-3-yl)-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 2-amino-N-((2R)-3-(cyclohexylmethoxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 15 2-amino-N-((2R)-3-(benzyloxy)-1-(3-methyl-4-oxo-1-phenyl-1,3,7-triazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-3-phenyl-2,6-diazaspiro[3.5]nonan-6-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-3-phenyl-2,6-diazaspiro[3.5]nonan-6-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 20 1-oxopropan-2-yl)-2-methylpropanamide;
- N-((2R)-3-(1H-Indol-3-yl)-1-(2-isopropyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-amino-2-methylpropanamide;
- 2-Amino-N-[(R)-1-benzyloxymethyl-2-(2-methyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl]-3-hydroxy-2-methyl-propionamide;
- 25 2-Amino-N-[(R)-1-(4-methoxy-benzyloxymethyl)-2-(2-methyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl]-2-methyl-propionamide;
- 2-Amino-N-[(R)-2-[4-(4-fluoro-phenyl)-2-methyl-1-oxo-2,7-diaza-spiro[4.5]dec-7-yl]-1-(4-ethoxy-benzyloxy methyl)-2-oxo-ethyl]-2-methyl-propionamide;
- 2-Amino-N-[(R)-1-(4-fluoro-benzyloxymethyl)-2-(2-methyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl]-2-methyl-propionamide;
- 30 2-Amino-N-[(R)-1-(3,4-difluoro-benzyloxymethyl)-2-(2-methyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl]-2-methyl-propionamide;
- 2-Amino-N-[(R)-1-(2,4-difluoro-benzyloxymethyl)-2-(2-methyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl]-2-methyl-propionamide;
- 35 2-amino-N-((2R)-3-(3-methoxybenzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

- 2-amino-N-((2R)-3-(2,4-difluorobenzyloxy)-1-(4-(3,4-difluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 2-amino-N-((2R)-3-(4-fluorobenzyloxy)-1-(2-methyl-1-oxo-4-p-tolyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 5 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(3,5-difluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 2-amino-N-((2R)-3-(3,4-difluorobenzyloxy)-1-(4-(3,4-difluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(3,4-difluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 10 2-amino-N-((2R)-1-(4-(3,4-difluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(4-fluorobenzyloxy)-1-oxopropan-2-yl)-2-methylpropanamide;
- 2-amino-N-(1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-4-(tetrahydro-2H-pyran-4-yl)butan-2-yl)-2-methylpropanamide;
- 15 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-((5-methylisoxazol-3-yl)methyl)-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-(oxazol-2-ylmethyl)-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 2-amino-N-((2R)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(2-methylbenzyloxy)-1-oxopropan-2-yl)-2-methylpropanamide;
- 20 2-amino-N-((2R)-3-(4-fluorobenzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- N-((2R)-3-(4-fluorobenzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methyl-2-(methylamino)propanamide;
- 25 N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methyl-2-(methylamino)propanamide;
- 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 2-amino-N-((2R)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(3-methylbenzyloxy)-1-oxopropan-2-yl)-2-methylpropanamide;
- 30 2-amino-N-((R)-3-(2,3-dihydro-1H-inden-2-yl)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- 2-amino-N-((2R)-1-(4-(4-fluorophenyl)-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-5-phenylpentan-2-yl)-2-methylpropanamide;
- 35 2-amino-N-((2R)-4-cyclohexyl-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxobutan-2-yl)-2-methylpropanamide;

- 2-amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-4-p-tolyl-2,7-diazaspiro[4.5]decan-7-yl)-3-(2-methylbenzyloxy)-1-oxopropan-2-yl)propanamide;
- 2-amino-2-methyl-N-((R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-5-phenylpent-4-en-2-yl)propanamide;
- 5 2-amino-N-((S)-3-(benzylthio)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
- N-((2R)-3-(4-fluorobenzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methyl-2-(methylamino)propanamide;
- 2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-p-tolyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxobutan-2-yl)-2-methylpropanamide;
- 10 2-amino-2-methyl-N-((R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-3-(pyridin-2-ylmethoxy)propan-2-yl)propanamide;
- 2-amino-N-((R)-3-(benzyloxy)-1-oxo-1-(1-oxo-4-phenyl-2-(2,2,2-trifluoroethyl)-2,7-diazaspiro[4.5]decan-7-yl)propan-2-yl)-2-methylpropanamide;
- 15 2-amino-N-((R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylbutanamide;
- N-((2R)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(4-methylbenzyloxy)-1-oxopropan-2-yl)-2-methyl-2-(methylamino)propanamide;
- 2-Amino-2-methyl-N-((R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro [4.5]decan-7-yl)-1-oxo-4-phenoxybutan-2-yl)propanamide;
- 20 4-phenoxybutan-2-yl)propanamide;
- or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt according to any one of claims 1 to 18 and one or more pharmaceutically acceptable carriers.

25

20. A combination comprising a therapeutically effective amount of the compound or salt according to any one of claims 1 to 18 and one or more therapeutically active co-agents.

21. A method of treating a disorder or a disease in a subject mediated by the ghrelin receptor, wherein the method comprises administering to the subject a therapeutically effective amount of the compound or salt according to any one of claims 1 to 18.

30

22. A compound or salt according to any one of claims 1 to 18, for use as a medicament.


35

23. A compound or salt according to any one of claims 1 to 18, for use in the treatment of a disorder or a disease mediated by the ghrelin receptor.

24. A compound or salt according to any one of claims 1 to 18, for use in the treatment of a disorder or a disease selected from gastroparesis (e.g. of diabetic, idiopathic or surgical origin), ileus (including post-operative ileus as well as ileus of drug-induced, ischemic, infectious and inflammatory origin), functional dyspepsia, short bowel syndrome, constipation such as associated with the hypomotility phase of irritable bowel syndrome (IBS), chronic intestinal pseudo-obstruction, delayed gastric emptying associated with wasting conditions, GERD, gastric ulcers and Crohn's disease, and emesis.
25. Use of a compound or salt according to any one of claims 1 to 18 in the manufacture of a medicament for the treatment of a disorder or a disease selected from gastroparesis (e.g. of diabetic, idiopathic or surgical origin), ileus (including post-operative ileus as well as ileus of drug-induced, ischemic, infectious and inflammatory origin), functional dyspepsia, short bowel syndrome, constipation such as associated with the hypomotility phase of irritable bowel syndrome (IBS), chronic intestinal pseudo-obstruction, delayed gastric emptying associated with wasting conditions, GERD, gastric ulcers and Crohn's disease, and emesis.

Claims

1. A compound of formula (I)



wherein

— is a single bond or a double bond;

X^1 is $(\text{CR}^{\text{x}1}\text{H})_n$ and X^2 is (CH) ; or

X^1 is $(\text{CR}^{\text{x}1}\text{H})_n$ and X^2 is N ; or

X^1 is $\text{NR}^{\text{x}1}$ and X^2 is (CH) ; or

X^1 is $\text{NR}^{\text{x}1}$ and X^2 is N ; or

X^1 is N and X^2 is C ; wherein the bond between X^1 and X^2 is a double bond if X^1 is N and X^2 is C ;

n is 0 or 1;

$\text{R}^{\text{x}1}$ is selected from hydrogen and C_{1-6} alkyl;

m is 1 and p is 0; or

m is 1 and p is 1; or

m is 2 and p is 1;

Y is NR^1 or O ;

R^1 is selected from hydrogen, C_{1-6} alkyl, $-\text{C}_{1-4}\text{alkylC}(\text{O})\text{NR}^{1a}\text{R}^{1b}$, $-\text{C}_{1-4}\text{alkylC}(\text{O})\text{OC}_{1-4}\text{alkyl}$, $-\text{C}_{1-4}\text{alkylC}(\text{O})\text{OC}_{1-4}\text{haloalkyl}$, $\text{C}_{1-6}\text{haloalkyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, $-\text{C}_{1-4}\text{alkyl-5-6 membered heteroaryl}$, $\text{hydroxyC}_{1-6}\text{alkyl}$, $\text{C}_{1-6}\text{alkoxy}$ and $\text{C}_{1-4}\text{alkoxyC}_{1-4}\text{alkyl}$;

wherein the 5-6 membered heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from halogen and C_{1-6} alkyl;

R^{1a} and R^{1b} are independently selected from hydrogen, C_{1-6} alkyl and $\text{C}_{1-6}\text{haloalkyl}$; or R^{1a} and R^{1b} together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring containing 0, 1 or 2 additional heteroatoms selected from oxygen, nitrogen and sulphur;

R^{2a} is selected from

(i) $-\text{A-phenyl}$;

(ii) $-\text{A-5-6 membered heteroaryl}$;

(iii) $-\text{A-4-6 membered heterocyclyl}$;

(iv) $-\text{A-C}_{5-6}\text{cycloalkyl}$;

(v) -D-8-10 membered fused bicyclic ring system;

wherein the phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, C₅₋₆cycloalkyl and 8-10 membered fused bicyclic ring system are unsubstituted or substituted with 1 to 3 substituents independently selected from halogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy and C₁₋₆haloalkyl;

A is selected from a bond, $-(CR^{A1}R^{A2})-$, $-(CR^{A1}R^{A2})(CR^{A1}R^{A2})-$, $-(CR^{A1}R^{A2})-O-$, $-O-(CR^{A1}R^{A2})-$, $-(CR^{A1}R^{A2})-S-$, $-(CR^{A1}R^{A2})-S(O)-$, $-(CR^{A1}R^{A2})-S(O)_2-$, $-S-(CR^{A1}R^{A2})-$, $-S(O)-(CR^{A1}R^{A2})-$, $-S(O)_2-(CR^{A1}R^{A2})-$, $-NR^{A3}-(CR^{A1}R^{A2})-$, $-(CR^{A1}R^{A2})-NR^{A3}-$ and $-(CR^{A1})=(CR^{A1})-$;

D is a bond, $-O-$ or $-(CR^{D1}R^{D2})-$;

R^{A1}, R^{A2} and R^{A3} are independently selected from hydrogen, C₁₋₆alkyl and halogen;

R^{D1} and R^{D2} are independently selected from hydrogen, C₁₋₆alkyl and halogen;

R^{2b} is hydrogen or C₁₋₄alkyl;


R³ and R⁴ are independently selected from hydrogen, C₁₋₆alkyl and C₃₋₆cycloalkyl; or R³ and R⁴ together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring containing 0, 1 or 2 additional heteroatoms selected from oxygen, nitrogen and sulphur; which 4-6 membered heterocyclic ring is unsubstituted or substituted with 1 or 2 halogen substituents;

R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆hydroxyalkyl and C₁₋₆haloalkyl;

R⁵ is selected from phenyl, a 5-6 membered heteroaryl, C₃₋₆cycloalkyl and 4-6 membered heterocyclyl; which phenyl, 5-6 membered heteroaryl, C₃₋₆cycloalkyl and 4-6 membered heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from halogen, C₁₋₆alkyl, C₁₋₆alkoxy and C₁₋₆haloalkyl;


or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein the compound is of formula (Ia)




wherein X¹ is (CR^{x1}H)_n and X² is (CH) or X¹ is NR^{x1} and X² is (CH).

3. The compound according to claim 1, wherein the compound is of formula (Ib)




wherein X^1 is $(CR^{x1}H)_n$ and X^2 is (CH) or X^1 is NR^{x1} and X^2 is (CH) .


4. The compound according to claim 1, wherein the compound is of formula (lc)



5. The compound according to claim 1, wherein the compound is of formula (ld)




6. The compound according to claim 1, wherein the compound is of formula (le)




wherein X^1 is $(CR^{x1}H)_n$ and X^2 is (CH) or X^1 is NR^{x1} and X^2 is (CH) .

7. The compound according to claim 1, wherein the compound is of formula (lf)




wherein X^1 is $(CR^{x1}H)_n$ and X^2 is (CH) or X^1 is NR^{x1} and X^2 is (CH) .

8. The compound according to claim 1, wherein the compound is of formula (lg)



wherein X^1 is $(CR^{x1}H)_n$ and X^2 is (CH) or X^1 is NR^{x1} and X^2 is (CH).

9. The compound according to claim 1, wherein the compound is of formula (lh)



wherein X^1 is $(CR^{x1}H)_n$ and X^2 is (CH) or X^1 is NR^{x1} and X^2 is (CH).

10. The compound according to any one of claims 1 to 9, wherein Y is NR^1 .

11. The compound according to any one of claims 1 to 10, wherein Y is NR^1 and R^1 is selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, $-C_{1-4}$ alkylC(O) $NR^{1a}R^{1b}$, $-C_{1-4}$ alkylC(O)OC $_{1-4}$ alkyl, and $-C_{1-4}$ alkyl-5-6 membered heteroaryl, wherein the 5-6 membered heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from halogen and C_{1-6} alkyl.

12. The compound according to any one of claims 1 to 11, wherein X^1 is $(CR^{x1}H)_n$.

13. The compound according to any one of claims 1 to 4, wherein X^1 is $(CR^{x1}H)_n$ and n is 1.

14. The compound according to any one of claims 1 to 13, wherein R^5 is selected from phenyl and a 5-6 membered heteroaryl, which phenyl or 5-6 membered heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from halogen and C_{1-6} alkyl.

15. The compound according to any one of claims 1 to 14, wherein R^{2a} is selected from -A-phenyl, -A-5-6 membered heteroaryl, -A-4-6 membered heterocyclyl, -A- C_{5-6} cycloalkyl and a -D-8-10 membered fused bicyclic ring system, which phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, -A- C_{5-6} cycloalkyl and 8-10 membered fused bicyclic ring

system are unsubstituted or substituted with 1 to 3 substituents independently selected from C₁₋₆alkyl, C₁₋₆alkoxy and halogen.

16. The compound according to any one of claims 1 to 15, wherein R³ and R⁴ are both hydrogen.

17. The compound according to any one of claims 1 to 16, wherein R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl and C₁₋₆hydroxyalkyl.

18. A compound according to claim 1, which is selected from

2-Amino-N-[(R)-1-benzyloxymethyl-2-(2-methyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl]-2-methyl-propionamide;

2-Amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-Amino-N-((2R)-3-(benzyloxy)-1-oxo-1-(1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)propan-2-yl)-2-methylpropanamide;

2-Amino-N-((2R)-3-(benzyloxy)-1-(2-isopropyl-1-oxo-4-phenyl-2,7-diaza spiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-Amino-N-((2R)-3-(benzyloxy)-1-(4-(4-chlorophenyl)-2-methyl-1-oxo-2,7-diaza spiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-Amino-N-((2R)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-Amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-3-(1-methyl-1H-indol-3-yl)-1-oxopropan-2-yl)propanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(2-ethyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-Amino-N-((2R)-1-(4-(4-fluorophenyl)-2-isopropyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(1-methyl-1H-indol-3-yl)-1-oxopropan-2-yl)-2-methyl propanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(2-(2-(dimethylamino)-2-oxoethyl)-1-oxo-4-phenyl-2,7-diaza spiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

N-((2R)-3-(Benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methyl-2-(methylamino) propanamide;

2-Amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-isopropyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-Amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro [4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

N-((2R)-3-(1H-indol-3-yl)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-amino-2-methylpropanamide;
 2-amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-5-phenylpentan-2-yl)propanamide;
 2-amino-N-((2R)-3-(benzyloxy)-1-(2-ethyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
 2-amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-4-phenylbutan-2-yl)propanamide;
 2-amino-N-((2R)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(4-methylbenzyloxy)-1-oxopropan-2-yl)-2-methylpropanamide;
 2-amino-N-((2R)-3-(3-methoxybenzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
 2-amino-N-((2R)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-5-phenylpentan-2-yl)-2-methylpropanamide;
 2-amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-5-phenylpentan-2-yl)propanamide;
 2-amino-N-((2R)-1-(4-(4-fluorophenyl)-2-isopropyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
 2-amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-3-phenyl-2,6-diazaspiro[3.5]nonan-6-yl)-3-(1-methyl-1H-indol-3-yl)-1-oxopropan-2-yl)propanamide;
 2-Amino-N-((R)-1-benzyloxymethyl-2-[2-(2,2-dimethyl-propyl)-1-oxo-4-phenyl-2,7-diazaspiro[4.5]dec-7-yl]-2-oxo-ethyl)-2-methyl-propionamide;
 2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxobutan-2-yl)-2-methylpropanamide;
 2-amino-N-((2R)-3-(benzyloxy)-1-(1-(4-fluorophenyl)-2-methyl-3-oxo-2,6-diazaspiro[3.5]nonan-6-yl)-1-oxopropan-2-yl)-2-methylpropanamide;
 2-Amino-N-((R)-1-benzyloxymethyl-2-(2-isobutyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]dec-7-yl)-2-oxo-ethyl)-2-methyl-propionamide;
 2-Amino-N-((R)-1-benzyloxymethyl-2-[4-(4-chloro-phenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]dec-7-yl]-2-oxo-ethyl)-2-methyl-propionamide;
 2-Amino-N-((R)-1-benzyloxymethyl-2-(2-isopropyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]dec-7-yl)-2-oxo-ethyl)-2-methyl-propionamide;
 2-Amino-N-((R)-1-benzyloxymethyl-2-(3-methyl-4-oxo-1-phenyl-2,3,7-triazaspiro[4.5]dec-1-en-7-yl)-2-oxo-ethyl)-2-methyl-propionamide;
 2-Amino-N-((R)-1-benzyloxymethyl-2-(3-methyl-4-oxo-1-phenyl-1,3,7-triazaspiro[4.5]dec-7-yl)-2-oxo-ethyl)-2-methyl-propionamide;

2-Amino-N-[(R)-1-benzyloxymethyl-2-oxo-2-(1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-ethyl]-2-methyl propionamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-o-tolyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-p-tolyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-3-(4-methylbenzyloxy)-1-oxopropan-2-yl)propanamide;

2-amino-N-((2R)-3-(4-chlorobenzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-(pyridin-3-yl)-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(cyclohexylmethoxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(3-methyl-4-oxo-1-phenyl-1,3,7-triazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-3-phenyl-2,6-diazaspiro[3.5]nonan-6-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-3-phenyl-2,6-diazaspiro[3.5]nonan-6-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

N-((2R)-3-(1H-Indol-3-yl)-1-(2-isopropyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-amino-2-methylpropanamide;

2-Amino-N-[(R)-1-benzyloxymethyl-2-(2-methyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl]-3-hydroxy-2-methyl-propionamide;

2-Amino-N-[(R)-1-(4-methoxy-benzyloxymethyl)-2-(2-methyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl]-2-methyl-propionamide;

2-Amino-N-[(R)-2-[4-(4-fluoro-phenyl)-2-methyl-1-oxo-2,7-diaza-spiro[4.5]dec-7-yl]-1-(4-ethoxy-benzyloxy methyl)-2-oxo-ethyl]-2-methyl-propionamide;

2-Amino-N-[(R)-1-(4-fluoro-benzyloxymethyl)-2-(2-methyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl]-2-methyl-propionamide;

2-Amino-N-[(R)-1-(3,4-difluoro-benzyloxymethyl)-2-(2-methyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl]-2-methyl-propionamide;

2-Amino-N-[(R)-1-(2,4-difluoro-benzyloxymethyl)-2-(2-methyl-1-oxo-4-phenyl-2,7-diaza-spiro[4.5]dec-7-yl)-2-oxo-ethyl]-2-methyl-propionamide;

2-amino-N-((2R)-3-(3-methoxybenzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(2,4-difluorobenzyloxy)-1-(4-(3,4-difluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(4-fluorobenzyloxy)-1-(2-methyl-1-oxo-4-p-tolyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(4-(3,5-difluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(3,4-difluorobenzyloxy)-1-(4-(3,4-difluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(4-(3,4-difluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-1-(4-(3,4-difluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(4-fluorobenzyloxy)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-(1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-4-(tetrahydro-2H-pyran-4-yl)butan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-((5-methylisoxazol-3-yl)methyl)-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-(oxazol-2-ylmethyl)-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(2-methylbenzyloxy)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-3-(4-fluorobenzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

N-((2R)-3-(4-fluorobenzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methyl-2-(methylamino)propanamide;

N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methyl-2-(methylamino)propanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(3-methylbenzyloxy)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((R)-3-(2,3-dihydro-1H-inden-2-yl)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-1-(4-(4-fluorophenyl)-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-5-phenylpentan-2-yl)-2-methylpropanamide;

2-amino-N-((2R)-4-cyclohexyl-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxobutan-2-yl)-2-methylpropanamide;

2-amino-2-methyl-N-((2R)-1-(2-methyl-1-oxo-4-p-tolyl-2,7-diazaspiro[4.5]decan-7-yl)-3-(2-methylbenzyloxy)-1-oxopropan-2-yl)propanamide;

2-amino-2-methyl-N-((R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-5-phenylpent-4-en-2-yl)propanamide;

2-amino-N-((S)-3-(benzylthio)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide;

N-((2R)-3-(4-fluorobenzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methyl-2-(methylamino)propanamide;

2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-p-tolyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxobutan-2-yl)-2-methylpropanamide;

2-amino-2-methyl-N-((R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxo-3-(pyridin-2-ylmethoxy)propan-2-yl)propanamide;

2-amino-N-((R)-3-(benzyloxy)-1-oxo-1-(1-oxo-4-phenyl-2-(2,2,2-trifluoroethyl)-2,7-diazaspiro[4.5]decan-7-yl)propan-2-yl)-2-methylpropanamide;

2-amino-N-((R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylbutanamide;

N-((2R)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-3-(4-methylbenzyloxy)-1-oxopropan-2-yl)-2-methyl-2-(methylamino)propanamide;

2-Amino-2-methyl-N-((R)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro [4.5]decan-7-yl)-1-oxo-4-phenoxybutan-2-yl)propanamide;

or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt according to any one of claims 1 to 18 and one or more pharmaceutically acceptable carriers.

20. A combination comprising a therapeutically effective amount of the compound or salt according to any one of claims 1 to 18 and one or more therapeutically active co-agents.

21. A compound or salt according to any one of claims 1 to 18, for use as a medicament.

22. A compound or salt according to any one of claims 1 to 18, for use in the treatment of a disorder or a disease mediated by the ghrelin receptor.

23. A compound or salt according to any one of claims 1 to 18, for use in the treatment of a disorder or a disease selected from gastroparesis (e.g. of diabetic, idiopathic or surgical origin), ileus (including post-operative ileus as well as ileus of drug-induced, ischemic, infectious and inflammatory origin), functional dyspepsia, short bowel syndrome, constipation such as associated with the hypomotility phase of irritable bowel syndrome (IBS), chronic intestinal pseudo-obstruction, delayed gastric emptying associated with wasting conditions, GERD, gastric ulcers and Crohn's disease, and emesis.

24. Use of a compound or salt according to any one of claims 1 to 18 in the manufacture of a medicament for the treatment of a disorder or a disease selected from gastroparesis (e.g. of diabetic, idiopathic or surgical origin), ileus (including post-operative ileus as well as ileus of drug-induced, ischemic, infectious and inflammatory origin), functional dyspepsia, short bowel syndrome, constipation such as associated with the hypomotility phase of irritable bowel syndrome (IBS), chronic intestinal pseudo-obstruction, delayed gastric emptying associated with wasting conditions, GERD, gastric ulcers and Crohn's disease, and emesis.